SV2009003152A - Derivados novedosos de aminopiridina que tiene accion inhibidora selectiva sobre aurora a - Google Patents

Derivados novedosos de aminopiridina que tiene accion inhibidora selectiva sobre aurora a

Info

Publication number
SV2009003152A
SV2009003152A SV2009003152A SV2009003152A SV2009003152A SV 2009003152 A SV2009003152 A SV 2009003152A SV 2009003152 A SV2009003152 A SV 2009003152A SV 2009003152 A SV2009003152 A SV 2009003152A SV 2009003152 A SV2009003152 A SV 2009003152A
Authority
SV
El Salvador
Prior art keywords
aminopiridine
novedous
aurora
derivatives
inhibiting action
Prior art date
Application number
SV2009003152A
Other languages
English (en)
Inventor
Iwasawa Yoshikazu
Kato Tetsuya
Kawanishi Nobuhiko
Masutani Kouta
Mita Takashi
Monoshita Katsumasa
Ohkubo Mitsuru
Original Assignee
Banyu Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Banyu Pharma Co Ltd filed Critical Banyu Pharma Co Ltd
Publication of SV2009003152A publication Critical patent/SV2009003152A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C07D241/22—Benzenesulfonamido pyrazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/20—Nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

LA PRESENTE INVENCIÓN SE REFIERE AL COMPUESTO DE FÓRMULA I: (VER FORMULA); EN EL QUE: R1 ES UN ÁTOMO DE HIDRÓGENO, F, CN, ETC.; R2 ES O, S, SO, S02, ETC.; R3 ES UN FENILO QUE PUEDE ESTAR SUSTITUIDO; X2 ES CH, N, ETC.; W ES EL SIGUIENTE RESTO: (VER FORMULA); EN EL QUE: W1, W2, Y W3 SON CADA UNO INDEPENDIENTEMENTE CH, N, ETC., O UNA DE SUS SALES ESTERES FARMACÉUTICAMENTE ACEPTABLES
SV2009003152A 2006-08-31 2009-01-14 Derivados novedosos de aminopiridina que tiene accion inhibidora selectiva sobre aurora a SV2009003152A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006236472 2006-08-31
US92608607P 2007-04-25 2007-04-25

Publications (1)

Publication Number Publication Date
SV2009003152A true SV2009003152A (es) 2009-04-28

Family

ID=39136042

Family Applications (1)

Application Number Title Priority Date Filing Date
SV2009003152A SV2009003152A (es) 2006-08-31 2009-01-14 Derivados novedosos de aminopiridina que tiene accion inhibidora selectiva sobre aurora a

Country Status (27)

Country Link
US (2) US7915263B2 (es)
EP (2) EP2062887B1 (es)
JP (3) JP2008081492A (es)
KR (1) KR20090055562A (es)
CN (1) CN101528731B (es)
AR (1) AR062585A1 (es)
AU (1) AU2007289609B2 (es)
CA (1) CA2657469C (es)
CL (1) CL2007002519A1 (es)
CO (1) CO6190529A2 (es)
CR (1) CR10553A (es)
EC (1) ECSP099062A (es)
ES (1) ES2389515T3 (es)
GT (1) GT200900008A (es)
HN (1) HN2009000113A (es)
IL (1) IL196497A0 (es)
MA (1) MA30719B1 (es)
MX (1) MX2009000390A (es)
NO (1) NO20091301L (es)
NZ (1) NZ574081A (es)
PE (1) PE20080835A1 (es)
RU (1) RU2437880C2 (es)
SV (1) SV2009003152A (es)
TW (1) TW200817363A (es)
UA (1) UA95972C2 (es)
WO (2) WO2008026768A1 (es)
ZA (1) ZA200900126B (es)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8519136B2 (en) 2008-02-22 2013-08-27 Msd K.K. Aminopyridine derivatives having aurora a selective inhibitory action
JP2011516464A (ja) * 2008-03-31 2011-05-26 サン・ファーマシューティカル・インダストリーズ・リミテッド モルフィナン類似体の改良された調製方法
JP5683462B2 (ja) * 2008-07-24 2015-03-11 ネルビアーノ・メデイカル・サイエンシーズ・エツセ・エルレ・エルレ オーロラキナーゼ阻害剤および抗増殖剤を含む治療用組み合わせ
NZ713361A (en) * 2009-08-17 2017-06-30 Memorial Sloan Kettering Cancer Center Heat shock protein binding compounds, compositions, and methods for making and using same
JP5878178B2 (ja) 2011-09-30 2016-03-08 大鵬薬品工業株式会社 １，２，４−トリアジン−６−カルボキサミド誘導体
TWI485146B (zh) * 2012-02-29 2015-05-21 Taiho Pharmaceutical Co Ltd Novel piperidine compounds or salts thereof
US9630896B2 (en) 2013-11-22 2017-04-25 Tansna Therapeutics, Inc. 2,5-dialkyl-4-H/halo/ether-phenol compounds
EP3143013B1 (en) 2014-05-13 2019-12-18 Memorial Sloan Kettering Cancer Center Hsp70 modulators and methods for making and using the same
TWI693218B (zh) 2014-11-14 2020-05-11 美商美國禮來大藥廠 極光ａ激酶抑制劑
US10866838B2 (en) * 2015-03-25 2020-12-15 Intel Corporation Cluster computing service assurance apparatus and method
CN108250191B (zh) * 2018-03-15 2020-10-20 兰州大学 一种3,5-二取代的2-氨基-吡嗪化合物及其制备工艺与应用
WO2020049208A1 (es) 2018-09-09 2020-03-12 Fundacio Privada Institut De Recerca De La Sida - Caixa Aurora cinasa como diana para tratar, prevenir o curar una infección por vih o sida
CN112898292A (zh) * 2019-12-03 2021-06-04 微境生物医药科技(上海)有限公司 新型极光激酶抑制剂及其用途
TWI785474B (zh) 2020-01-22 2022-12-01 大陸商北京加科思新藥研發有限公司 用作選擇性Aurora A抑制劑的新型雜環化合物
WO2023196887A1 (en) 2022-04-08 2023-10-12 Eli Lilly And Company Method of treatment including kras g12c inhibitors and aurora a inhibitors

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
OA07174A (fr) 1981-08-24 1984-04-30 May & Baker Ltd Nouvelles imidazotétrazionones, leur préparation et les médicaments qui les contiennent.
JPS6019790A (ja) 1983-07-14 1985-01-31 Yakult Honsha Co Ltd 新規なカンプトテシン誘導体
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
US5223608A (en) 1987-08-28 1993-06-29 Eli Lilly And Company Process for and intermediates of 2',2'-difluoronucleosides
ES2137932T3 (es) 1990-09-28 2000-01-01 Smithkline Beecham Corp Procedimiento para la preparacion de analogos de camptotecina solubles en agua, asi como los compuestos 10-hidroxi-11-alcoxi-6-camptotecina.
US5191082A (en) 1990-12-20 1993-03-02 North Carolina State University Camptothecin intermediate and method of making camptothecin intermediates
US5247089A (en) 1990-12-20 1993-09-21 North Carolina State University Method of making intermediates useful for the manufacture of camptothecin and camptothecin analogs
US5200524A (en) 1990-12-20 1993-04-06 North Carolina State University Camptothecin intermediates and method of making same
US5162532A (en) 1990-12-20 1992-11-10 North Carolina State University Intermediates and method of making camptothecin and camptothecin analogs
US5243050A (en) 1990-12-20 1993-09-07 North Carolina State University Alkylpyridone DE ring intermediates useful for the manufacture of camptothecin and camptothecin analogs
DK0666868T4 (da) 1992-10-28 2006-09-18 Genentech Inc Anvendelse af anti-VEGF-antistoffer til behandling af cancer
JP3025602B2 (ja) 1993-05-21 2000-03-27 デビオファーム エス．アー． 光学的に高純度なシス−オキザラート（トランス−ｌ−１，２−シクロヘキサンジアミン）白金（ＩＩ）錯体の製造方法
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
JPH11507535A (ja) 1995-06-07 1999-07-06 イムクローン システムズ インコーポレイテッド 腫瘍の成長を抑制する抗体および抗体フラグメント類
JP3154399B2 (ja) 1996-07-04 2001-04-09 デビオファーム エス．アー． 白金化合物の製造方法
PE92198A1 (es) 1996-08-01 1999-01-09 Banyu Pharma Co Ltd Derivados de 1,4-piperidina disustituida que contienen fluor
WO2001017995A1 (en) 1999-09-10 2001-03-15 Merck & Co., Inc. Tyrosine kinase inhibitors
EP1578341A4 (en) 2000-10-11 2005-09-28 Tularik Inc MODULATION OF THE CCR4 FUNCTION
US20020137755A1 (en) 2000-12-04 2002-09-26 Bilodeau Mark T. Tyrosine kinase inhibitors
ATE326462T1 (de) 2000-12-21 2006-06-15 Vertex Pharma Pyrazolverbindungen als protein-kinase- inhibitoren
US7144903B2 (en) 2001-05-23 2006-12-05 Amgen Inc. CCR4 antagonists
WO2006008874A1 (ja) * 2004-05-21 2006-01-26 Banyu Pharmaceutical Co., Ltd. アミノチアゾール骨格を有するＣｄｋ４，６選択的阻害剤
US7491720B2 (en) * 2004-10-29 2009-02-17 Banyu Pharmaceutical Co., Ltd. Aminopyridine derivatives having Aurora A selective inhibitory action
EP1828165B1 (en) * 2004-10-29 2013-03-20 Msd K.K. Novel aminopyridine derivatives having aurora a selective inhibitory action
TW200628463A (en) 2004-11-10 2006-08-16 Synta Pharmaceuticals Corp Heteroaryl compounds
GB0428082D0 (en) 2004-12-22 2005-01-26 Welcome Trust The Ltd Therapeutic compounds
EP1833807A1 (en) 2005-01-05 2007-09-19 Rigel Pharmaceuticals, Inc. Ubiquitin ligase inhibitors
EP1876178B1 (en) * 2005-04-28 2015-05-27 Mitsubishi Tanabe Pharma Corporation Cyanopyridine derivative and use thereof as medicine
WO2006124874A2 (en) 2005-05-12 2006-11-23 Kalypsys, Inc. Inhibitors of b-raf kinase
WO2006129842A1 (ja) * 2005-06-01 2006-12-07 Banyu Pharmaceutical Co., Ltd. オーロラa選択的阻害作用を有する新規アミノピリジン誘導体
US7572809B2 (en) * 2005-12-19 2009-08-11 Hoffmann-La Roche Inc. Isoquinoline aminopyrazole derivatives

Also Published As

Publication number Publication date
AR062585A1 (es) 2008-11-19
AU2007289609B2 (en) 2012-02-02
WO2008026769A1 (fr) 2008-03-06
JP2010047602A (ja) 2010-03-04
JP5256168B2 (ja) 2013-08-07
ES2389515T3 (es) 2012-10-26
TW200817363A (en) 2008-04-16
JPWO2008026769A1 (ja) 2010-01-21
EP2061782A1 (en) 2009-05-27
EP2062887A1 (en) 2009-05-27
PE20080835A1 (es) 2008-06-14
JP2008081492A (ja) 2008-04-10
EP2061782A4 (en) 2010-03-31
IL196497A0 (en) 2009-09-22
EP2062887A4 (en) 2010-03-31
CA2657469C (en) 2013-07-02
CL2007002519A1 (es) 2008-02-08
NZ574081A (en) 2011-08-26
GT200900008A (es) 2010-10-04
AU2007289609A1 (en) 2008-03-06
ZA200900126B (en) 2010-01-27
WO2008026768A1 (en) 2008-03-06
MX2009000390A (es) 2009-01-29
JP4466782B2 (ja) 2010-05-26
MA30719B1 (fr) 2009-09-01
EP2062887B1 (en) 2012-07-04
CO6190529A2 (es) 2010-08-19
KR20090055562A (ko) 2009-06-02
US7915263B2 (en) 2011-03-29
HN2009000113A (es) 2014-01-06
US20100016335A1 (en) 2010-01-21
CR10553A (es) 2009-06-28
UA95972C2 (ru) 2011-09-26
CA2657469A1 (en) 2008-03-06
CN101528731A (zh) 2009-09-09
ECSP099062A (es) 2009-02-27
NO20091301L (no) 2009-04-30
RU2437880C2 (ru) 2011-12-27
RU2009111599A (ru) 2010-10-10
CN101528731B (zh) 2014-05-07
US20080058347A1 (en) 2008-03-06

Similar Documents

Publication Publication Date Title
SV2009003152A (es) Derivados novedosos de aminopiridina que tiene accion inhibidora selectiva sobre aurora a
GT200600339A (es) Inhibidores macrociclicos del virus de la hepatitis c
GT200500238A (es) Fenilaminotiazoles sustituidos y su uso
UY30499A1 (es) Derivados de amina utiles como agentes anticancerigenos
GT200500240A (es) Nuevos herbicidas
ECSP11010902A (es) Combinaciones sinérgicas de un inhibidor macrocíclico del vhc y un nucleósido
CL2012000311A1 (es) Compuestos derivados que contiene ciclos con 3 atomos de nitrogeno; utiles en el tratamiento de parasitosis en animales.
ECSP066780A (es) Inhibidores de polimerasa viral
CY1109610T1 (el) Παραγωγο βενζιμιδαζολης και η χρηση αυτου ως ανταγωνιστου του υποδοχεα αιι
ECSP11010912A (es) Compuestos de pirrol
NO20091871L (no) Hepatitt C virus inhibitorer
DE502006005460D1 (de) Bohrspülung enthaltend hydrophobin
UY30105A1 (es) Derivados nuevos azufrados de urea cíclica, su preparación y su utilización farmacéutica como inhibidores de quinasas.
AR062797A1 (es) Derivados de piperidina como inhibidores de renina, composiciones farmaceuticas.
PA8667201A1 (es) Nuevos compuestos farmaceuticos
CR9590A (es) Derivados de n-(heteroaril)-1-heteroarilalquil-1h-indol-2-carboxamida su prepracion y su aplicacion en terapeutica
CO6190626A2 (es) Compuestos y composiciones como inhibidores de proteasa activadora de canal
CR11245A (es) Mejoras en compuestos organicos o relacionadas con los mismos
ATE466838T1 (de) Sulfonamid-derivate als lebercarnitin-palmitoyl- transferase-hemmer
ECSP099065A (es) Derivados de cinamoil-piperazina y su utilización como antagonistas de par-1
CO6331307A2 (es) Derivados de imidazo[1,2alfa]piridin-2-carboxamidas su preparacion y su aplicacion en terapeutica
ECSP099546A (es) Nuevos derivados tricíclicos, su procedimiento de preparación
CO6251285A2 (es) Derivado de tetrahidroisoquinolina novedoso
PA8644201A1 (es) Hexadecasacaridos biotinilados, su preparacion y utilizacion
ATE551330T1 (de) Heterocyclische cetp-hemmer